Genmab A/S ADS (GMAB)

Price$25.45

Value ScoreC

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-28.70%

Price vs S&P 500 (4W)-2.01%

VGM Score46.20

Market Capitalization$101.48B

P/E Ratio (Annual)16.44x

All Metrics

P/CF (Annual)13.35x

Book Value / Share (Quarterly)$92.57

P/TBV (Annual)4.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)21.97%

Cash Flow / Share (Quarterly)$14.21

Price vs S&P 500 (YTD)-25.93%

Gross Margin (TTM)93.31%

Net Profit Margin (TTM)21.05%

EPS (TTM)$13.20

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$13.20

Revenue Growth (5Y)19.19%

EPS (Annual)$15.36

ROI (Annual)8.54%

Gross Margin (Annual)93.60%

Net Profit Margin (5Y Avg)32.29%

Cash / Share (Quarterly)$24.78

P/E Basic Excl Extra (TTM)19.28x

Revenue Growth QoQ (YoY)25.31%

EPS Growth (5Y)6.82%

P/E Normalized (Annual)16.44x

ROA (Last FY)7.48%

Revenue Growth TTM (YoY)20.72%

EBITD / Share (TTM)$17.70

ROE (5Y Avg)17.15%

Operating Margin (TTM)27.10%

Cash Flow / Share (Annual)$18.35

P/B Ratio2.79x

P/B Ratio (Quarterly)3.00x

Net Income / Employee (Annual)$317,900

EV / Revenue (TTM)5.04x

Net Interest Coverage (TTM)15.44x

ROA (TTM)8.48%

EPS Growth QoQ (YoY)-72.79%

EV / EBITDA (TTM)17.70x

EPS Incl Extra (Annual)$15.36

Current Ratio (Annual)2.02x

Quick Ratio (Quarterly)2.17x

3-Month Avg Trading Volume0.15M

52-Week Price Return-34.04%

EV / Free Cash Flow (Annual)17.38x

P/E Incl Extra (TTM)19.28x

Revenue / Employee (TTM)$1,287,900

Tangible BV / Share (Quarterly)$65.02

P/S Ratio (Annual)4.26x

Asset Turnover (Annual)0.29x

52-Week High$2257.00

Operating Margin (5Y Avg)34.07%

EPS Excl Extra (Annual)$15.36

CapEx CAGR (5Y)3.22%

Tangible BV CAGR (5Y)10.66%

26-Week Price Return-12.77%

Quick Ratio (Annual)2.01x

13-Week Price Return-8.07%

Total Debt / Equity (Annual)0.93x

Current Ratio (Quarterly)2.18x

Enterprise Value$19.66B

Revenue / Share Growth (5Y)20.38%

Asset Turnover (TTM)0.40x

Book Value / Share Growth (5Y)14.61%

Revenue / Employee (Annual)$1,228,100

Inventory Turnover (Annual)17.89x

Pretax Margin (Annual)32.37%

Cash / Share (Annual)$27.83

3-Month Return Std Dev30.78%

Gross Margin (5Y Avg)97.53%

Net Income / Employee (TTM)$271,000

EBITDA CAGR (5Y)2.32%

EBITDA Interim CAGR (5Y)17.24%

ROE (Last FY)16.47%

Net Interest Coverage (Annual)1.70x

EPS Basic Excl Extra (Annual)$15.36

P/FCF (TTM)14.00x

Receivables Turnover (TTM)4.42x

EV / Free Cash Flow (TTM)22.55x

Total Debt / Equity (Quarterly)0.94x

EPS Incl Extra (TTM)$13.20

Receivables Turnover (Annual)3.67x

ROI (TTM)9.76%

P/S Ratio (TTM)4.06x

Pretax Margin (5Y Avg)40.72%

Revenue / Share (Annual)$59.34

Tangible BV / Share (Annual)$53.22

Forward P/E19.65x

Free OCF CAGR (5Y)3.84%

Price vs S&P 500 (52W)-44.04%

P/E Ratio (TTM)19.28x

EPS Growth TTM (YoY)-25.28%

Year-to-Date Return-15.93%

5-Day Price Return-1.13%

EPS Normalized (Annual)$15.36

ROA (5Y Avg)13.54%

Net Profit Margin (Annual)25.89%

Month-to-Date Return0.83%

Cash Flow / Share (TTM)$32.63

EBITD / Share (Annual)$17.85

EPS Growth (3Y)9.58%

Operating Margin (Annual)28.63%

LT Debt / Equity (Annual)0.86x

P/CF (TTM)17.55x

ROI (5Y Avg)15.25%

P/E Excl Extra (TTM)19.28x

LT Debt / Equity (Quarterly)0.87x

EPS Basic Excl Extra (TTM)$13.20

P/TBV (Quarterly)4.82x

P/B Ratio (Annual)3.33x

Inventory Turnover (TTM)15.82x

Pretax Margin (TTM)26.51%

Book Value / Share (Annual)$94.89

Price vs S&P 500 (13W)-17.81%

Net Margin Growth (5Y)-11.26%

Beta0.55x

P/FCF (Annual)14.00x

Revenue / Share (TTM)$61.09

ROE (TTM)14.54%

52-Week Low$1275.00

vGradeC

gGradeC

mGradeD

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.65

3.69

3.70

3.78

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GMABGenmab A/S ADS	C	C	D	$25.45
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Genmab is a Copenhagen-based biotechnology company developing antibody therapeutics for cancer treatment, leveraging proprietary platforms including DuoBody, HexaBody, and DuoHexaBody. The company has a portfolio of approved products including Darzalex (the standard of care for multiple myeloma), Tepezza, Kesimpta, and others developed through strategic partnerships with major pharmaceutical companies. Genmab maintains a pipeline of candidates targeting additional oncologic indications.